Overall, the distribution of the 125 cases across the various AML groups was as follows: 15 (12%) t(15;17) AML; 7 (5.6%) t(8;21) AML; 6 (4.8%) inv(16)/t(16;16) AML; 8 (6.4%) KMT2A(MLL) AML; 88 (70.4%) other AML; and 1 (0.8%) non-AML. The gene discussed is KMT2A; the disease is acute myeloid leukemia.